{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:34:54Z","timestamp":1773048894444,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515220170"],"award-info":[{"award-number":["2021A1515220170"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40273-024-01412-9","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:02:40Z","timestamp":1719986560000},"page":"1111-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission\u2013Economic Evaluation Model"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0498-0662","authenticated-orcid":false,"given":"Yawen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiatong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"1412_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/1471-2334-14-480","volume":"14","author":"M Biggerstaff","year":"2014","unstructured":"Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14:480.","journal-title":"BMC Infect Dis"},{"issue":"25","key":"1412_CR2","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","volume":"360","author":"FS Dawood","year":"2009","unstructured":"Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605\u201315.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"1412_CR3","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1093\/infdis\/jiz043","volume":"219","author":"MC Crank","year":"2019","unstructured":"Crank MC, Mascola JR, Graham BS. Preparing for the next influenza pandemic: the development of a universal influenza vaccine. J Infect Dis. 2019;219(Supplement_1):S107\u20139.","journal-title":"J Infect Dis"},{"key":"1412_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmph.2022.101314","volume":"21","author":"A D'Adamo","year":"2023","unstructured":"D\u2019Adamo A, Schnake-Mahl A, Mullachery PH, Lazo M, Diez Roux AV, Bilal U. Health disparities in past influenza pandemics: a scoping review of the literature. SSM Popul Health. 2023;21: 101314.","journal-title":"SSM Popul Health."},{"issue":"26","key":"1412_CR5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","volume":"34","author":"F Berlanda Scorza","year":"2016","unstructured":"Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34(26):2926\u201333.","journal-title":"Vaccine"},{"issue":"1","key":"1412_CR6","first-page":"1","volume":"60","author":"AE Fiore","year":"2011","unstructured":"Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(1):1\u201324.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"1412_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217307","volume":"14","author":"K Fukao","year":"2019","unstructured":"Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, et al. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS ONE. 2019;14(5): e0217307.","journal-title":"PLoS ONE"},{"issue":"10","key":"1412_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204\u201314.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"1412_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"1412_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/cts.13237","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, Retout S, Duval V, Jia J, Zou Y, Wang Y, et al. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil Chinese individuals. Clin Transl Sci. 2022;15(5):1196\u2013203.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"1412_CR11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1086\/523584","volume":"45","author":"A McGeer","year":"2007","unstructured":"McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568\u201375.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1412_CR12","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/cid\/ciz101","volume":"69","author":"T Lytras","year":"2019","unstructured":"Lytras T, Mouratidou E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study. Clin Infect Dis. 2019;69(11):1896\u2013902.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1412_CR13","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1038\/s41467-020-16585-y","volume":"11","author":"Z Du","year":"2020","unstructured":"Du Z, Nugent C, Galvani AP, Krug RM, Meyers LA. Modeling mitigation of influenza epidemics by baloxavir. Nat Commun. 2020;11(1):2750.","journal-title":"Nat Commun"},{"issue":"11","key":"1412_CR14","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1093\/cid\/ciaa1622","volume":"72","author":"T Komeda","year":"2021","unstructured":"Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, et al. Comparison of household transmission of influenza virus from index patients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis. 2021;72(11):e859\u201367.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1412_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.medj.2023.11.001","volume":"5","author":"W Guan","year":"2024","unstructured":"Guan W, Qu R, Shen L, Mai K, Pan W, Lin Z, et al. Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus. Medicine. 2024;5(1):32-41.e5.","journal-title":"Medicine"},{"key":"1412_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.849545","volume":"13","author":"J Qin","year":"2022","unstructured":"Qin J, Lin J, Zhang X, Yuan S, Zhang C, Yin Y. Evaluation of the clinical effectiveness of oseltamivir for influenza treatment in children. Front Pharmacol. 2022;13: 849545.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1412_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010797","volume":"19","author":"J Asher","year":"2023","unstructured":"Asher J, Lemenuel-Diot A, Clay M, Durham DP, Mier-Y-Teran-Romero L, Arguello CJ, et al. Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLoS Comput Biol. 2023;19(1): e1010797.","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"1412_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciac068","volume":"75","author":"S Miyazawa","year":"2022","unstructured":"Miyazawa S, Takazono T, Hosogaya N, Yamamoto K, Watanabe H, Fujiwara M, et al. Comparison of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database. Clin Infect Dis. 2022;75(6):927\u201335.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1412_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1412_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132588","volume":"10","author":"R Liu","year":"2015","unstructured":"Liu R, Leung RK, Chen T, Zhang X, Chen F, Chen S, et al. The effectiveness of age-specific isolation policies on epidemics of influenza A (H1N1) in a large city in central south China. PLoS ONE. 2015;10(7): e0132588.","journal-title":"PLoS ONE"},{"issue":"3","key":"1412_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.epidem.2012.06.001","volume":"4","author":"A Cori","year":"2012","unstructured":"Cori A, Valleron AJ, Carrat F, Scalia Tomba G, Thomas G, Bo\u00eblle PY. Estimating influenza latency and infectious period durations using viral excretion data. Epidemics. 2012;4(3):132\u20138.","journal-title":"Epidemics"},{"issue":"2","key":"1412_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/irv.12534","volume":"12","author":"B Lina","year":"2018","unstructured":"Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Virus. 2018;12(2):267\u201378.","journal-title":"Influenza Other Respir Virus"},{"issue":"03","key":"1412_CR23","first-page":"218","volume":"14","author":"J Li","year":"2020","unstructured":"Li J, Teng J, Tian GB, Xia C, Wang X, Chien-Ping T. Analysis on the current situation of pathogen monitoring and antiviral treatment of influenza-like cases in Beijing Haidian Hospital from 2017 to 2019. Chin J Exp Clin Infect Dis (Electron Edn). 2020;14(03):218\u201323.","journal-title":"Chin J Exp Clin Infect Dis (Electron Edn)"},{"issue":"9","key":"1412_CR24","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1073\/pnas.1415012112","volume":"112","author":"W Yang","year":"2015","unstructured":"Yang W, Lipsitch M, Shaman J. Inference of seasonal and pandemic influenza transmission dynamics. Proc Natl Acad Sci USA. 2015;112(9):2723\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1412_CR25","unstructured":"(CDC) CfDCaP. Effectiveness of 2008\u201309 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)\u2014United States May\u2013June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(44):1241\u20135."},{"issue":"3","key":"1412_CR26","first-page":"346","volume":"221","author":"T Uehara","year":"2020","unstructured":"Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020;221(3):346\u201355.","journal-title":"J Infect Dis"},{"key":"1412_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-0-85729-148-6_2","volume-title":"Numerical methods for ordinary differential equations","author":"DF Griffiths","year":"2010","unstructured":"Griffiths DF, Higham DJ. Euler\u2019s method. In: Griffiths DF, Higham DJ, editors. Numerical methods for ordinary differential equations. London: Springer; 2010. p. 19\u201331."},{"issue":"1","key":"1412_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1089\/bsp.2006.4.84","volume":"4","author":"E Toner","year":"2006","unstructured":"Toner E. Do public health and infection control measures prevent the spread of flu? Biosecur Bioterror. 2006;4(1):84\u20136.","journal-title":"Biosecur Bioterror"},{"key":"1412_CR29","unstructured":"Shionogi & CO. L. Clinical Study Report: 1601T0831. 2018. Available from https:\/\/classic.clinicaltrials.gov\/ProvidedDocs\/54\/NCT02954354\/Prot_000.pdf. Accessed 01 Feb 2022."},{"key":"1412_CR30","unstructured":"Shionogi & CO. L. Clinical Study Report: 1602T0832. 2018. Available from https:\/\/www.shionogi.com\/content\/dam\/shionogi\/jp\/innovation\/rd\/clinical-development\/clinical-trialdata\/pdf\/033188_T0832_csr_synop_E.pdf. Accessed 01 Feb 2022."},{"issue":"12","key":"1412_CR31","first-page":"751","volume":"100","author":"DY Gaitonde","year":"2019","unstructured":"Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Phys. 2019;100(12):751\u20138.","journal-title":"Am Fam Phys"},{"key":"1412_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40249-015-0077-6","volume":"4","author":"J Yang","year":"2015","unstructured":"Yang J, Jit M, Leung KS, Zheng YM, Feng LZ, Wang LP, et al. The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey. Infect Dis Poverty. 2015;4:44.","journal-title":"Infect Dis Poverty"},{"issue":"12","key":"1412_CR33","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1080\/21645515.2021.1996151","volume":"17","author":"N Jiang","year":"2021","unstructured":"Jiang N, Li R, Bao J, Xie Y, Ma X, He Y, et al. Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources. Hum Vaccin Immunother. 2021;17(12):5638\u201345.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1412_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12906-020-03141-w","volume":"20","author":"S Wang","year":"2020","unstructured":"Wang S, Liu L, Liu J, Miao L, Zhuang Q, Guo N, et al. Characteristics of prescriptions and costs for acute upper respiratory tract infections in Chinese outpatient pediatric patients: a nationwide cross-sectional study. BMC Complement Med Ther. 2020;20(1):346.","journal-title":"BMC Complement Med Ther"},{"issue":"50","key":"1412_CR35","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1016\/j.vaccine.2016.10.051","volume":"34","author":"KA Maurer","year":"2016","unstructured":"Maurer KA, Chen HF, Wagner AL, Hegde ST, Patel T, Boulton ML, et al. Cost-effectiveness analysis of pneumococcal vaccination for infants in China. Vaccine. 2016;34(50):6343\u20139.","journal-title":"Vaccine"},{"key":"1412_CR36","unstructured":"Yaozh. The winning price of the drug 2022. Available from https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed 15 Jan 2023."},{"key":"1412_CR37","unstructured":"National Bureau of Statistics of China. Consumer price index 2021. Available from https:\/\/data.stats.gov.cn\/english\/easyquery.htm?cn=A01. Accessed 20 April 2024."},{"issue":"7","key":"1412_CR38","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/bcp.13229","volume":"83","author":"MA Kamal","year":"2017","unstructured":"Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, et al. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol. 2017;83(7):1580\u201394.","journal-title":"Br J Clin Pharmacol"},{"key":"1412_CR39","doi-asserted-by":"publisher","DOI":"10.3310\/hta13110","author":"P Tappenden","year":"2009","unstructured":"Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009. https:\/\/doi.org\/10.3310\/hta13110.","journal-title":"Health Technol Assess"},{"issue":"1","key":"1412_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amepre.2023.01.028","volume":"65","author":"Y Gong","year":"2023","unstructured":"Gong Y, Yao X, Peng J, Ma Y, Fang Y, Yan K, et al. Cost-effectiveness and health impacts of different influenza vaccination strategies for children in China. Am J Prev Med. 2023;65(1):155\u201364.","journal-title":"Am J Prev Med"},{"issue":"3","key":"1412_CR41","doi-asserted-by":"publisher","first-page":"ofz053","DOI":"10.1093\/ofid\/ofz053","volume":"6","author":"Y Wang","year":"2019","unstructured":"Wang Y, Fan G, Horby P, Hayden F, Li Q, Wu Q, et al. Comparative outcomes of adults hospitalized with seasonal influenza A or B virus infection: application of the 7-category ordinal scale. Open Forum Infect Dis. 2019;6(3):ofz053.","journal-title":"Open Forum Infect Dis"},{"key":"1412_CR42","unstructured":"Macroeconomics and health: Investing in health for economic development. WHO Commission on Macroeconomics and Health; 2001."},{"key":"1412_CR43","unstructured":"China NBoSo. Statistical Communiqu\u00e9 of the People's Republic of China on the 2021 National Economic and Social Development 2022. Available from http:\/\/www.stats.gov.cn\/english\/PressRelease\/202202\/t20220227_1827963.html."},{"issue":"5","key":"1412_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Mak. 2012;32(5):722\u201332.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1412_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/0962280211419832","volume":"24","author":"G Baio","year":"2015","unstructured":"Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Stat Methods Med Res. 2015;24(6):615\u201334.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"1412_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"19","key":"1412_CR47","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/jama.2020.6173","volume":"323","author":"H Sakamoto","year":"2020","unstructured":"Sakamoto H, Ishikane M, Ueda P. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA. 2020;323(19):1969\u201371.","journal-title":"JAMA"},{"issue":"4","key":"1412_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0272989X211045070","volume":"42","author":"J Bilcke","year":"2021","unstructured":"Bilcke J, Beutels P. Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice. Med Decis Mak. 2021;42(4):421\u201335.","journal-title":"Med Decis Mak"},{"key":"#cr-split#-1412_CR49.1","unstructured":"Diseases JNIoI. Influenza 2017\/18 season, Japan. Infectious agents surveillance report"},{"key":"#cr-split#-1412_CR49.2","unstructured":"2018. Contract No. 2018. 39(Nov): p. 3."},{"issue":"7","key":"1412_CR50","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/03007995.2021.1914942","volume":"37","author":"M Dronova","year":"2021","unstructured":"Dronova M, Ikeoka H, Itsumura N, Hirotsu N, Ansaripour A, Aball\u00e9a S, et al. Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan. Curr Med Res Opin. 2021;37(7):1135\u201348.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1412_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1098\/rsif.2006.0161","volume":"4","author":"G Chowell","year":"2007","unstructured":"Chowell G, Nishiura H, Bettencourt LMA. Comparative estimation of the reproduction number for pandemic influenza from daily case notification data. J R Soc Interface. 2007;4(12):155\u201366.","journal-title":"J R Soc Interface"},{"issue":"19","key":"1412_CR52","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.1073\/pnas.1000886107","volume":"107","author":"AJ Valleron","year":"2010","unstructured":"Valleron AJ, Cori A, Valtat S, Meurisse S, Carrat F, Bo\u00eblle PY. Transmissibility and geographic spread of the 1889 influenza pandemic. Proc Natl Acad Sci USA. 2010;107(19):8778\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1412_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IM9.0000000000000006","volume":"1","author":"X Fu","year":"2019","unstructured":"Fu X, Zhou Y, Wu J, Liu X, Ding C, Huang C, et al. A severe seasonal influenza epidemic during 2017\u20132018 in China after the 2009 pandemic influenza: a modeling study. Infect Microb Dis. 2019;1(1):20\u20136.","journal-title":"Infect Microb Dis"},{"key":"1412_CR54","doi-asserted-by":"crossref","unstructured":"The Lancet Infectious D. What is the pandemic potential of avian influenza A(H5N1)? Lancet Infect Dis. 2024;24(5):437.","DOI":"10.1016\/S1473-3099(24)00238-X"},{"issue":"11","key":"1412_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166180","volume":"11","author":"T Chen","year":"2016","unstructured":"Chen T, Chen T, Liu R, Xu C, Wang D, Chen F, et al. Transmissibility of the influenza virus during influenza outbreaks and related asymptomatic infection in mainland China, 2005\u20132013. PLoS ONE. 2016;11(11): e0166180.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01412-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:54:16Z","timestamp":1726667656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01412-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01412-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"17 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was based on simulation. Therefore, ethical approvals were not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This work was supported by Guangdong Basic and Applied Basic Research Foundation (2021A1515220170) and F. Hoffmann-La Roche Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y.J. and Y.S. conceived the study and secured funding. Y.J. and J.W. reviewed the literature, constructed the model, and analyzed the data. Y.J., J.W., and J.S. interpreted the data and drafted the manuscript. Y.S. reviewed and critically revised the paper. J.S. provided administrative and logistic support. All authors gave final approval for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data used in the study are provided in the manuscript. The modeling file and the data used in the model have been submitted for editorial and peer review and is available online. ().","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and availability"}},{"value":"Y.J. and Y.S. received research funding from F. Hoffmann-La Roche Ltd and Sanofi Pasteur. J.W. and J.S. declare they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}